Loading [Contrib]/a11y/accessibility-menu.js
Review

Pharmacological effect of Allium sativum on coagulation, blood pressure, diabetic nephropathy, neurological disorders, spermatogenesis, antibacterial effects

  • Received: 27 December 2018 Accepted: 17 April 2019 Published: 29 April 2019
  • For many years, the medicinal plants have been used all over the world for treating and preventing from some diseases. But the effects of some of them have been examined scientifically. The medicinal plants are useful treating methods in both traditional and modern systems. The allium species like garlic and onion are used as food, spices, flavor and local drugs. With the scientific name of Allium sativam, the garlic is from the Liliaceae family and it has attracted a special attention among the modern plants, because it has been spread and is available all over the world. The findings of this study indicate that the garlic consuming can increase infection of some of bacteria. Due to the antioxidant characteristics, the garlic is likely to reduce these hurts significantly through increasing the antioxidant capacity in the kidney. There are several reports on the anticoagulation characteristics of garlic. Also there are some warnings about the simultaneous consumption of the garlic with warfarin and nonsteroidal anti-inflammation drugs. And also, garlic has anti-hypertensive characteristics and its compounds have been investigated in treating infertility, according to the studies done, garlic and the old garlic’s extract have anti-stress, anti-aging, memory and learning improving and anti-Alzheimer characteristics. But more studies are needed to be done on the humans in this context.

    Citation: Seyyed Abbas Hashemi, Sayeh Ghorbanoghli, Ali Asghar Manouchehri, Mahdi Babaei Hatkehlouei. Pharmacological effect of Allium sativum on coagulation, blood pressure, diabetic nephropathy, neurological disorders, spermatogenesis, antibacterial effects[J]. AIMS Agriculture and Food, 2019, 4(2): 386-398. doi: 10.3934/agrfood.2019.2.386

    Related Papers:

    [1] Larrell L. Wilkinson, Saundra H. Glover, Janice C. Probst, Bo Cai, Lisa T. Wigfall . Psychological Distress and Health Insurance Coverage among Formerly Incarcerated Young Adults in the United States. AIMS Public Health, 2015, 2(3): 227-246. doi: 10.3934/publichealth.2015.3.227
    [2] Shervin Assari . Differential protective effects of Family Income-to-Poverty-Ratio on electronic cigarette, depression, and obesity of Black and White Americans. AIMS Public Health, 2024, 11(4): 1157-1171. doi: 10.3934/publichealth.2024060
    [3] Karent Zorogastua, Pathu Sriphanlop, Alyssa Reich, Sarah Aly, Aminata Cisse, Lina Jandorf . Breast and Cervical Cancer Screening among US and non US Born African American Muslim Women in New York City. AIMS Public Health, 2017, 4(1): 78-93. doi: 10.3934/publichealth.2017.1.78
    [4] Alexios Batrakoulis, Oscar L Veiga, Susana Franco, Ewan Thomas, Antonios Alexopoulos, Manel Valcarce-Torrente, Rita Santos-Rocha, Fatima Ramalho, Andrea Di Credico, Daniela Vitucci, Liliana Ramos, Vera Simões, Alejandro Romero-Caballero, Isabel Vieira, Annamaria Mancini, Antonino Bianco . Health and fitness trends in Southern Europe for 2023: A cross-sectional survey. AIMS Public Health, 2023, 10(2): 378-408. doi: 10.3934/publichealth.2023028
    [5] Alexios Batrakoulis, Saeid Fatolahi, Farnaz Dinizadeh . Health and fitness trends in Iran for 2024: A cross-sectional study. AIMS Public Health, 2023, 10(4): 791-813. doi: 10.3934/publichealth.2023053
    [6] Pamila Sadeeka Adikari, KGRV Pathirathna, WKWS Kumarawansa, PD Koggalage . Role of MOH as a grassroots public health manager in preparedness and response for COVID-19 pandemic in Sri Lanka. AIMS Public Health, 2020, 7(3): 606-619. doi: 10.3934/publichealth.2020048
    [7] Marybeth Gasman, Tiffany Smith, Carmen Ye, Thai-Huy Nguyen . HBCUs and the Production of Doctors. AIMS Public Health, 2017, 4(6): 579-589. doi: 10.3934/publichealth.2017.6.579
    [8] Keith Elder, Keon Gilbert, Louise Meret Hanke, Caress Dean, Shahida Rice, Marquisha Johns, Crystal Piper, Jacqueline Wiltshire, Tondra Moore, Jing Wang . Disparities in Confidence to Manage Chronic Diseases in Men. AIMS Public Health, 2014, 1(3): 123-136. doi: 10.3934/publichealth.2014.3.123
    [9] Quynh Nhu (Natasha) B. La Frinere-Sandoval, Catherine Cubbin, Diana M. DiNitto . Perceived neighborhood social cohesion and cervical and breast cancer screening utilization among U.S.-born and immigrant women. AIMS Public Health, 2022, 9(3): 559-573. doi: 10.3934/publichealth.2022039
    [10] Casey T. Harris, Kevin Fitzpatrick, Michael Niño, Priya Thelapurath, Grant Drawve . Examining disparities in the early adoption of Covid-19 personal mitigation across family structures. AIMS Public Health, 2022, 9(3): 589-605. doi: 10.3934/publichealth.2022041
  • For many years, the medicinal plants have been used all over the world for treating and preventing from some diseases. But the effects of some of them have been examined scientifically. The medicinal plants are useful treating methods in both traditional and modern systems. The allium species like garlic and onion are used as food, spices, flavor and local drugs. With the scientific name of Allium sativam, the garlic is from the Liliaceae family and it has attracted a special attention among the modern plants, because it has been spread and is available all over the world. The findings of this study indicate that the garlic consuming can increase infection of some of bacteria. Due to the antioxidant characteristics, the garlic is likely to reduce these hurts significantly through increasing the antioxidant capacity in the kidney. There are several reports on the anticoagulation characteristics of garlic. Also there are some warnings about the simultaneous consumption of the garlic with warfarin and nonsteroidal anti-inflammation drugs. And also, garlic has anti-hypertensive characteristics and its compounds have been investigated in treating infertility, according to the studies done, garlic and the old garlic’s extract have anti-stress, anti-aging, memory and learning improving and anti-Alzheimer characteristics. But more studies are needed to be done on the humans in this context.


    1. Introduction

    MDMA (3,4 methylene-dioxymetamphetamine), also known as Ecstasy is a phenethylamine that is similar to both amphetamine and methamphetamine [1,2]. MDMA possesses potent stimulant qualities but is different from amphetamines and methamphetamine in that MDMA has a particular affinity for the serotonin transporter [2]. MDMA was first synthesized nearly one hundred years ago (1912) and due to its purported ability to elicit empathy gained some initial notoriety as an adjunct used during couples therapy in the 1970’s. MDMA became popular as a street drug in the 1980’s and was made illegal in 1985 [3]. MDMA is usually taken in tablet form with a standard dose of 0.75-4.0 mg per kilogram of body weight [4]. MDMA users report rapid onset, euphoria, added energy, and enhanced closeness to others [5,6]. Despite these pleasurable effects, users can also report anxiety and irritability, impulsiveness, paranoia, muscle cramps, potentially fatal hyperthermia, and mood changes that heighten aggression [1,7,8,9].

    In 1990’s and early 2000’s there was an alarming rise in the availability and use of synthetic “club drugs” most notable of which is Ecstasy (MDMA). The use of ecstasy at large youth parties known as “raves” has garnered an abundance of electronic and print media attention. Several recent studies of MDMA-assisted psychotherapy for post-traumatic stress disorder have emerged showing possible promising results [10].

    At various junctures in time, the cultural context of MDMA has changed from being considered a love, hug, and general party drug. More recent research suggests, however, that MDMA users may also be engaged in relatively high levels of violent and non-violent crime. Reid and colleagues [11] found a connection between MDMA use and aggression among 260 young adult MDMA users. Specifically, young adult MDMA users who were most aggressive were those low on a measure of self-control suggesting that impulsivity is the behavioral mechanism by which MDMA is linked to aggression.

    Insufficient research exists relative to the nature of MDMA use and crime and violence. In a Scottish study of 209 participants recruited from dance clubs, Hammersley et al. [12], found MDMA users were involved in a wide range of illegal activities but also commonly used other illicit substances. Yacoubian et al. [13] collected self-report drug use data and urine specimens from 209 youthful offenders and found that 16% reported using MDMA within the past year, which is significantly higher than non-offending youth. In a prospective longitudinal investigation of four years Lieb et al. [14], concluded that mental health disorders are associated with multiple substances including MDMA. Confounding of prior and current mental health problems and substance abuse underscores the difficulty in identifying a relationship between MDMA use and crime given that the vast majority of MDMA users evince a polydrug use career. In addition, generalizability is an issue as there have been no studies of MDMA use and crime in population- based samples.

    The purpose of the present study is to surmount prior limitations in examining the MDMA-crime link. We do so by employing data sourced from the National Epidemiologic Survey of Alcohol and Related Conditions (NESARC). NESARC is a nationally representative sample that is ideally suited to the present study due to its generalizability and extensive assessment of drug use, mental health disorders, and antisocial behavior. We hypothesize that MDMA use will be associated with both violent and non-violent crime even after controlling for notable confounds such as alcohol and other illicit drug use, mental health disorders, and sociodemographic characteristics.

    2. Methods

    Study findings are based on data from Waves I (2001-2002) and II (2004-2005) of the National Epidemiologic Survey of Alcohol and Related Conditions (NESARC). The NESARC is a nationally representative sample of non-institutionalized U.S. residents aged 18 years and older. The NESARC utilized a multistage cluster sampling design, oversampling young adults, Hispanics, and African-Americans in the interest of obtaining reliable statistical estimation in these subpopulations, and to ensure appropriate representation of racial/ethnic subgroups. Data were collected through face-to-face structured psychiatric interviews conducted by U.S. Census workers trained by the National Institute on Alcohol Abuse and Alcoholism and U.S. Census Bureau. Data were weighted at the individual and household levels to adjust for oversampling and non-response on demographic variables (i.e., age, race/ethnicity, sex, region, and place of residence). Data were also adjusted to be representative (based on region, age, race, and ethnicity) of the U.S. adult population as assessed during the 2000 Census. The U.S. Census Bureau and the U.S. Office of Management and Budget approved the research protocol and informed consent procedures. The response rate for Wave I data was 81% and for Wave II was 87% with a cumulative response rate of 70% for both waves. Based on the distribution of MDMA users in the general population, the current study restricted analyses to adults between the ages of 18 and 49 (n = 19, 073). A more detailed description of the NESARC design and procedures is available elsewhere [15].

    2.1. Measures

    MDMAUsers. Respondents were asked, “Have you ever used ecstasy or MDMA?” Data from Waves I and II were combined to measure respondent self-report of lifetime Ecstasy/MDMA use (0 = no, 1 = yes).

    2.1.1. Crime and Violence

    Twelve dichotomous (0 = no, 1 = yes) measures from the antisocial personality disorder module of the Alcohol Use Disorder and Associated Disabilities Interview Schedule--DSM-IV version (AUDADIS-IV) were used to examine criminal and violent behavior. Data from Waves I and II were combined to measure respondent self-report of having exhibited any of the behaviors in their lifetime. In addition to the twelve single-item measures, we also created two additional dichotomous measures of involvement in any of the criminal and violent behaviors examined in the study. Specifically, individuals who responded affirmatively to one or more of the criminal behavior variables were coded as 1 while those who did not respond affirmatively to any of the criminal behavior variables were coded as 0. An identical coding procedure was implemented with respect to any lifetime involvement in violent behavior (0 = no lifetime involvement in any violent behavior, 1 = lifetime involvement in one or more violent behaviors). Only variables measuring nonviolent criminal and violent behaviors with prevalence greater than 3% were included in statistical analyses.

    2.1.2. Sociodemographic and Behavioral Controls

    The following demographic variables were included as controls: age, gender, race/ethnicity, household income, education level, marital status, region of the United States, and urbanicity. To better isolate the link between MDMA use and crimogenic variables we also controlled for parental history of antisocial behavior, parental substance use problems, lifetime use of other licit or illicit substances (i.e., alcohol, cannabis, cocaine/crack, amphetamines, inhalants, tranquilizers, and heroin) and lifetime diagnoses of clinical and personality disorders.

    2.2. Data analysis

    A series of logistic regression analyses were conducted that compared the criminal and violent behavior of MDMA users with non-users while controlling for aforementioned variables. Stratified logistic regression was carried out to examine the links between MDMA use and crime/violence across gender. Weighted prevalence estimates and associated 95% confidence intervals were computed using Stata 13.1 SE software[16]. This system implements a Taylor series linearization to adjust estimates for complex survey sampling design effects including clustered data. Estimates for all analyses were obtained using Wave 2 weights. Additional information regarding the weighting procedures utilized in the analyses of NESARC data is available elsewhere [17]. Adjusted odds ratios (AORs) were considered to be statistically significant if the associated confidence intervals did not cross the 1.0 threshold.

    3. Results

    Table 1 displays the sociodemographic characteristics of individuals between the ages of 18 and 49 reporting having ever used MDMA. Compared to nonusers, individuals reporting having used MDMA were significantly more likely to be male (AOR = 1.69, 95% CI = 1.57-1.83), to reside in a household earning less than $20, 000 per year (AOR = 1.44, 95% CI = 1.24-1.67), to have completed some college (AOR = 1.20, 95% CI = 1.11-1.29), and to be either separated/divorced (AOR = 1.68, 95% CI = 1.40-2.03) or never married (AOR = 1.88, 95% CI = 1.73-2.05). MDMA users were significantly less likely to be between the ages of 18 and 34 (AOR = 0.23, 95% CI = 0.20-0.26), to be either African-American (AOR = 0.14, 95% CI = 0.12-0.17) or Hispanic (AOR = 0.64, 95% CI = 0.57-0.72), to have graduated from high school only (AOR = 0.86, 95% CI = 0.78-0.94) and to reside in a region other than the Western United States. No significant differences were observed in terms of urbanicity.

    Table 1. Sociodemographic characteristics of MDMA users in the United States
    Note: Adjusted odds ratios adjusted for age, race/ethnicity, household income, education level, region of the United States, and urbanicity. Odds ratios and confidence intervals in bold are statistically significant.
    Ever used ecstasy or MDMA? Unadjusted Adjusted
    Sociodemographic Factors No (n = 18, 548; 96.80%) Yes (n = 519; 3.20%)
    % 95% CI % 95% CI OR (95% CI) OR (95% CI)
    Age
    18-34 years 43.80 (43.3-44.3) 80.51 (78.7-82.2) 0.19 (0.17-0.21) 0.23 (0.20-0.26)
    35-49 years 56.20 (55.7-56.7) 19.49 (17.8-21.3) 1.00 1.00
    Gender
    Female 50.99 (50.5-51.4) 37.00 (35.5-38.5) 1.00 1.00
    Male 49.01 (48.6-49.4) 63.00 (61.4-64.5) 1.77 (1.66-1.89) 1.69 (1.57-1.83)
    Race/Ethnicity
    Non-Hispanic White 65.30 (64.6-65.9) 75.01 (73.0-76.9) 1.00 1.00
    African American 12.53 (12.0-13.0) 2.70 (2.3-3.1) 0.19 (0.16-0.22) 0.14 (0.12-0.17)
    Hispanic 6.94 (6.7-7.2) 9.15 (7.8-10.6) 0.75 (0.68-0.83) 0.64 (0.57-0.72)
    Other 15.23 (14.9-15.6) 13.14 (12.3-14.0) 1.15 (0.95-1.39) 1.04 (0.86-1.27)
    Household Income
    < , 000 16.12 (15.7-16.5) 25.53 (23.5-27.6) 1.99 (1.75-2.27) 1.44 (1.24-1.67)
    , 000-, 999 17.46 (17.1-17.8) 18.64 (16.8-20.6) 1.34 (1.16-1.56) 1.09 (0.94-1.7)
    , 000-, 999 34.02 (33.6-34.4) 30.10 (28.6-31.6) 1.11 (1.01-1.23) 0.96 (0.86-1.07)
    > , 000 32.40 (32.0-32.8) 25.73 (23.9-27.6) 1.00 1.00
    Education Level
    Less than H.S. 11.30 (11.0-11.6) 10.18 (8.7-11.8) 0.99 (0.84-1.17) 0.92 (0.76-1.12)
    H.S. Graduate 25.33 (24.8-25.9) 20.35 (18.8-22.0) 0.88 (0.79-0.99) 0.86 (0.78-0.94)
    Some College 24.07 (23.7-24.4) 33.79 (30.2-35.4) 1.55 (1.43-1.67) 1.20 (1.11-1.29)
    Completed AA, BA, or Technical Degree 39.30 (38.8-39.8) 35.68 (34.0-37.4) 1.00 1.00
    Marital Status
    Married/ Cohabitating 62.66 (62.2-53.1) 39.42 (37.9-41.0) 1.00 1.00
    Separated/Divorced 10.75 (10.5-11.1) 9.20 (7.9-10.7) 1.36 (1.14-1.63) 1.68 (1.40-2.03)
    Widowed 0.58 (0.52-0.65) 0.16 (0.15-0.17) 0.43 (0.38-0.50) 0.73 (0.48-1.10)
    Never Married 26.00 (25.5-26.5) 51.22 (49.6-52.9) 3.13 (2.91-3.36) 1.88 (1.73-2.05)
    Region of U.S.A.
    West 17.19 (16.7-17.6) 15.41 (14.3-16.6) 1.00 1.00
    Northeast 18.50 (18.1-18.9) 18.32 (16.8-20.0) 0.70 (0.61-0.79) 0.72 (0.63-0.82)
    Midwest 39.20 (38.7-39.7) 33.94 (31.9-36.0) 0.77 (0.67-0.88) 0.78 (0.67-0.90)
    South 25.11 (24.7-25.5) 32.33 (30.4-34.3) 0.67 (0.60-0.75) 0.62 (0.55-0.70)
    Urbanicity
    Rural 67.55 (66.9-68.2) 68.76 (67.5-70.0) 1.00 1.00
    Urban 32.45 (31.8-33.1) 31.24 (30.0-32.5) 0.95 (0.89-1.00) 0.97 (0.90-1.05)
     | Show Table
    DownLoad: CSV

    Figure 1 displays the lifetime prevalence of criminal and violent behavior among male and female MDMA users and nonusers. Across gender, the prevalence of criminal and violent behavior was greater among MDMA users compared to non-MDMA users. Moreover, with the exception of injuring someone in a fight, the prevalence of crime and violence among female MDMA users was greater than that of male nonusers. With the exception of intimate partner violence, the prevalence of all of criminal and violent behaviors was greater among male MDMA users compared to female MDMA users.

    Figure 1. Prevalence of crime and violence among MDMA users in the United States.

    Table 2 compares the prevalence of violent and criminal behavior among MDMA users in contrast with nonusers. Controlling for sociodemographic factors, parental antisocial and substance use characteristics, lifetime substance use, and psychiatric morbidity, MDMA users were significantly more likely to report involvement in all criminal and violent behaviors examined in this study. Supplementary stratified logistic regression analyses yielded additional information with respect to the behaviors of MDMA users across gender. With respect to crime, robust effects were observed for both women (AOR = 1.94, 95% CI = 1.64-2.31) and men (AOR = 1.77, 95% CI = 1.47-2.14); however, while the odds ratio was slightly larger for women, no significant differences in effects were observed. Significant gender differences were observed in terms of the relationship between MDMA use and violence. Namely, while male MDMA users were significantly more likely to enact violence (AOR = 1.73, 95% CI = 1.51-2.00), female MDMA users were found to be significantly less likely to enact violence compared to female nonusers when controlling for sociodemographic factors, parental antisocial and substance use characteristics, lifetime substance use, and psychiatric morbidity (AOR = 0.77, 95% CI = 0.63-0.94).

    Table 2. Crime and Violence among MDMA users in the United States
    Note:Adjusted odds ratios adjusted for age, gender, race/ethnicity, household income, education level, marital status, region of the United States, urbanicity, parental history of antisocial behavior and substance abuse history, lifetime substance use (alcohol, cannabis, cocaine/crack, amphetamines, inhalants, tranquilizers, and heroin) and lifetime diagnosis of any clinical or personality disorder.
    Ever used ecstasy or MDMA? Unadjusted Adjusted
    No (n = 18, 548; 96.80%) Yes (n = 519; 3.20%)
    % 95% CI % 95% CI OR (95% CI) AOR (95% CI)
    Crime
    Do things that could have easily hurt
    you or someone else - like speeding or
    driving after having too much to drink?
    No 81.06 (80.7-81.4) 47.81 (45.9-49.7) 1.00 1.00
    Yes 18.94 (18.6-19.3) 52.19 (50.3-54.1) 4.67 (4.29-5.09) 1.40 (1.25-1.56)
    Shoplift?
    No 85.90 (85.6-86.2) 53.22 (51.4-35.0) 1.00 1.00
    Yes 14.10 (13.8-14.4) 46.78 (45.0-48.6) 5.35 (4.96-5.78) 1.27 (1.14-1.42)
    Steal anything from someone or
    someplace when no one was around?
    No 89.09 (88.8-89.4) 64.04 (62.3-65.7) 1.00 1.00
    Yes 10.91 (10.6-11.2) 35.96 (34.3-37.7) 4.58 (4.23-4.97) 1.44 (1.28-1.63)
    Destroy, break, or vandalize someone
    else's property?
    No 94.96 (94.7-95.1) 74.19 (72.1-76.2) 1.00 1.00
    Yes 5.04 (4.8-5.2) 25.81 (23.8-27.9) 6.55 (5.85-7.33) 1.53 (1.28-1.81)
    Made money illegally like selling stolen
    property or selling drugs?
    No 96.44 (96.2-96.6) 68.85 (66.9-70.7) 1.00 1.00
    Yes 3.56 (3.4-3.7) 31.15 (29.3-33.0) 12.2 (11.2-13.4) 1.64 (1.41-1.91)
    Do anything that you could have been
    arrested for?
    No 79.38 (78.9-79.8) 30.78 (29.2-32.5) 1.00 1.00
    Yes 20.62 (20.2-21.0) 69.22 (67.5-70.8) 8.66 (8.03-9.34) 1.58 (1.42-1.76)
    Violence
    Bullied or pushed people around or tried
    to make them afraid of you?
    No 91.65 (91.4-91.9) 77.28 (75.1-79.3) 1.00 1.00
    Yes 8.35 (8.1-8.6) 22.72 (20.7-24.9) 3.23 (2.84-3.67) 1.21 (1.02-1.45)
    Get into a lot of fights that you started?
    No 96.54 (96.3-96.7) 85.99 (84.4-87.5) 1.00 1.00
    Yes 3.46 (3.3-3.6) 14.01 (12.5-15.6) 4.54 (3.95-5.22) 1.34 (1.08-1.66)
    Hit someone so hard that you injure them
    or they had to see a doctor?
    No 92.35 (92.0-92.7) 76.64 (74.7-78.5) 1.00 1.00
    Yes 7.65 (7.3-8.0) 23.36 (21.5-25.3) 3.68 (3.28-4.13) 1.24 (1.03-1.49)
    Get into a fight that came to swapping
    blows with romantic partner?
    No 91.97 (91.7-92.2) 81.34 (80.1-82.5) 1.00 1.00
    Yes 8.03 (7.8-8.3) 18.66 (17.5-19.9) 2.63 (2.41-2.86) 1.28 (1.13-1.45)
    Use a weapon like a stick, knife, or gun
    in a fight?
    No 96.88 (96.7-97.0) 86.98 (85.4-88.4) 1.00 1.00
    Yes 3.12 (3.0-3.3) 13.02 (11.6-14.6) 4.64 (4.00-5.39) 1.98 (1.65-2.36)
    Physically hurt another person in any
    way on purpose?
    No 93.15 (92.9-93.4) 75.07 (73.0-77.0) 1.00 1.00
    Yes 6.85 (6.6-7.1) 24.93 (23.0-26.9) 4.51 (4.01-5.08) 1.46 (1.23-1.73)
     | Show Table
    DownLoad: CSV

    4. Discussion

    Our objective was to examine the association between MDMA and crime and violence and assess the robustness of the relation by controlling for numerous confounds. To our knowledge, this is the largest study ever conducted on MDMA and crime. We found that MDMA users, both male and female, were involved in a number of crimes in acts of violence including drunk driving, shoplifting, theft, intimate partner violence, and fighting. Notably, female MDMA users were more antisocial than male non-MDMA users. Although adjusting the results for numerous confounds attenuated the relationships, MDMA users were still at significantly greater odds of engaging in violence and nonviolent crime than non- MDMA users. These findings support prior research that indicated that MDMA is associated with aggression [11]. Given that violence has been established as a major health concern, it is important to point out illicit drug is linked to both violence and poor health. Although MDMA use is substantially less than that of alcohol and other substances found to be associated with violence, it nevertheless is a contributor to the drugs-violence public health nexus.

    It is not entirely clear as to the mechanism(s) by which MDMA is associated with crime and violence. Reid and colleagues [11] found that MDMA users were more impulsive and therefore more likely to be reactively aggressive. Investigations on adults who use MDMA suggest that this drug generates persistent damage to serotonin-releasing neurons[1] and that MDMA is a powerful selective serotonin neurotoxin [18,19]. Multiple studies have found psychiatric disorders such as anxiety and depression is relatively common among MDMA users [20,21,22]. Serotonin transporter dysfunction has been linked to violence in several studies [23]. It could also simply be the case that individuals with difficult temperaments are more likely to use MDMA and be anger and crime-prone [24].

    Despite the many assets of the study, several limitations should be noted. One limitation is the data are cross-sectional. Although we control for a substantial number of confounds, we are unable to clarify the temporal ordering of associations in the data. Thus, the causal status of MDMA use and crime and violence is not established. Moreover, we do not know the long-term status that MDMA use has on crime and violence. This will require data from prospective longitudinal designs. An additional limitation is that the data did not include important contextual information (e.g., situations of use) which could be used in understanding the MDMA-crime connection. Future studies on MDMA should consider these data features.

    5. Conclusion

    Like many drugs of abuse, MDMA has had a multifaceted career. Whether thought of as a facilitator of empathy and closeness (i.e., love and hugs) or as a pathway to crime and violence (i.e., mugging), new research on the behavioral effects of MDMA are needed to clarify its proper role. The current study suggests that MDMA is associated with a broad array of crimes and transgressions at the population-level for both male and female users. Although additional tests of the MDMA-crime link are needed to properly inform policy, findings from this national study suggest that there are public health consequences to the proliferation and ingestion of MDMA.

    Acknowledgments

    NESARC was funded by the National Institute on Alcohol Abuse and Alcoholism with additional support provided by the National Institute on Drug Abuse.

    Conflict of Interest

    The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the article.



    [1] Rivlin RS (2001) Historical perspective on the use of garlic. J Nutr 131: 951–954. doi: 10.1093/jn/131.3.951S
    [2] Jiang Y, David B, Tu P, et al. (2010) Recent analytical approaches in quality control of traditional Chinese medicines-a review. Anal Chim Acta 657: 9–18. doi: 10.1016/j.aca.2009.10.024
    [3] Nagourney RA (1998) Garlic: Medicinal food or nutritious medicine? J Med Food 1: 13–28. doi: 10.1089/jmf.1998.1.13
    [4] Tattelman E (2005) Health effects of garlic. Am Fam Physician 72: 103–106.
    [5] Avecina A (1991) Ghanoon in Medicine: 458–465.
    [6] Koch HP, Lawson LD (1995) Garlic: The Science and Therapeutic Application of Allium Sativum L. and Related Species. Baltimore: Williams & Wilkins, 34–108.
    [7] Mathew BC, Daniel RS, Augusti KT (1996) Hypolipidemic effect of garlic protein substituted for casein in diet of rats compared to those of garlic oil. Indian J Exp Biol 34: 337–340.
    [8] Anwar MM, Meki AR (2003) Oxidative stress in streptozotocin-induced diabetic rats: Effects of garlic oil and melatonin. Comp Biochem Physiol A Mol Integr Physiol 135: 539–547. doi: 10.1016/S1095-6433(03)00114-4
    [9] Pedraza-Chaverri J, Yam-Canul P, Chirino YI, et al. (2008) Protective effects of garlic powder against potassium dichromateinduced oxidative stress and nephrotoxicity. Food Chem Toxicol46: 619–627.
    [10] Liu CT, Sheen LY, Lii CK (2007) Does garlic have a role as an antidiabetic agent? Mol Nutr Food Res 51: 1353–1364. doi: 10.1002/mnfr.200700082
    [11] El-Demerdash FM, Yousef MI, El-Naga NI (2005) Biochemical study on the hypoglycemic effects of onion and garlic in alloxan-induced diabetic rats. Food Chem Toxicol 43: 57–63. doi: 10.1016/j.fct.2004.08.012
    [12] Liu CT, Hse H, Lii CK, et al. (2005) Effects of garlic oil and diallyl trisulfide on glycemic control in diabetic rats. Eur J Pharmacol 516: 165–173. doi: 10.1016/j.ejphar.2005.04.031
    [13] Cruz C, Correa-Rotter R, Sánchez-González DJ, et al. (2007) Renoprotective and antihypertensive effects of S-allylcysteine in 5/6 nephrectomized rats. Am J Physiol Renal Physiol 293: F1691–F1698. doi: 10.1152/ajprenal.00235.2007
    [14] Mensah-Brown EP, Obineche EN, Galadari S, et al. (2005) Streptozotocin-induced diabetic nephropathy in rats: The role of inflammatory cytokines. Cytokine 31: 180–190. doi: 10.1016/j.cyto.2005.04.006
    [15] Yin MC, Hsu CC, Chiang PF, et al. (2007) Antiinflammatory and antifibrogenic effects of s-ethyl cysteine and s-methyl cysteine in the kidney of diabetic mice. Mol Nutr Food Res 51: 572–579. doi: 10.1002/mnfr.200600213
    [16] Maldonado PD, Barrera D, Rivero I, et al. (2003) Antioxidant S-allylcysteine prevents gentamicin-induced oxidative stress and renal damage. Free Radic Biol Med 35: 317–324. doi: 10.1016/S0891-5849(03)00312-5
    [17] Moreno FJ, Corzo-Martı´nez M, del Castillo MD, et al. (2006) Changes in antioxidant activity of dehydrated onion and garlic during storage. Food Res Int 39: 891–897. doi: 10.1016/j.foodres.2006.03.012
    [18] Hamada Y, Fukagawa M (2007) A possible role of thioredoxin interacting protein in the pathogenesis of streptozotocin-induced diabetic nephropathy. Kobe J Med Sci 53: 53–61.
    [19] O'Bryan GT, Hostetter TH (1997) The renal hemodynamic basis of diabetic nephropathy. Semin Nephrol 17: 93–100.
    [20] Kalantarinia K, Awad AS, Siragy HM (2003) Urinary and renal interstitial concentrations of TNF-alpha increase prior to the rise in albuminuria in diabetic rats. Kidney Int 64: 1208–1213. doi: 10.1046/j.1523-1755.2003.00237.x
    [21] Shiju TM, Rajesh NG, Viswanathan P (2013) Renoprotective effect of aged garlic extract in streptozotocin-induced diabetic rats. Indian J Pharmacol 45: 18–23. doi: 10.4103/0253-7613.106429
    [22] Moriguchi T, Takasugi N, Itakura Y (2001) The effects of aged garlic extract on lipid peroxidation and the deformability of erythrocytes. J Nutr 131: 1016S–1019S. doi: 10.1093/jn/131.3.1016S
    [23] Fukao H, Yoshida H, Tazawa Y, et al. (2007) Antithrombotic effects of odorless garlic powder both in vitro and in vivo. Biosci Biotechnol Biochem 71: 84–90. doi: 10.1271/bbb.60380
    [24] Yeh YY, Liu L (2001) Cholesterol lowering effect of garlic extracts and organosulphur compounds: Human and animal studies. J Nutr 131: 989S–993S. doi: 10.1093/jn/131.3.989S
    [25] Saravanan G, Ponmurugan P, Kumar GPS, et al. (2009) Anti-diabetic properties of S-allylcysteine, a garlic component on streptozotocin induced diabetes in rats. J App Biomed 7: 151–159. doi: 10.32725/jab.2009.017
    [26] Wang X, Jiao F, Wang QW, et al. (2012) Aged black garlic extract induces inhibition of gastric cancer cell growth in vitro and in vivo. Mol Med Rep 5: 66–72.
    [27] Bautista-Garcia P, Sanchez-Lozada LG, Cristobal-Garcia M, et al. (2006) Chronic inhibition of NOS-2 ameliorates renal inhury, as well as COX-2 and TGF-beta 1 overexpression in 5/6 nephrectomized rats. Nephrol Dial Transplant 21: 3074–3081. doi: 10.1093/ndt/gfl444
    [28] Fujihara CK, Antunes GR, Mattar AL, et al. (2007) Chronic inhibition of nuclear factor-kappa B attenuates renal injury in the 5/6 renal ablation model. Am J Physiol Ren Physiol 292: F92–99. doi: 10.1152/ajprenal.00184.2006
    [29] Maldonado PD, Barrera D, Medina-Campos ON, et al. (2003) Aged garlic extract attenuates gentamicin induced renal damage and oxidative stress in rats. Lif Sci 73: 2543–2556. doi: 10.1016/S0024-3205(03)00609-X
    [30] Wongmekiat O, Thamprasert K (2005) Investigating the protective effects of aged garlic extract on cyclosporine induced nephrotoxicity in rats. Fundam Clin Pharmacol 19: 555–562. doi: 10.1111/j.1472-8206.2005.00361.x
    [31] Kabasakal L, Sehiril O, Cetinel S, et al. (2005) Protective effect of aqueous garlic extract against renal ischemia/reperfusion injury in rats. J Med Food 8: 319–326. doi: 10.1089/jmf.2005.8.319
    [32] Seckiner I, Bayrak O, Can M, et al. (2014) Garlic supplemented diet attenuates gentamicin nephrotoxicity ın rats. Int Braz J Urol 40: 562–567. doi: 10.1590/S1677-5538.IBJU.2014.04.17
    [33] Mahady GB, Matsuura H, Pendland SL (2004) Allixin, a phytoalexin from garlic, inhibits the growth of Helicobacter pylori in vitro. Am J Gastroenterol 96: 3454–3455.
    [34] O'Gara E, Hill D, Maslin D (2000) Activities of garlic oil, garlic powder, and their diallyl constituents against helicobacter pylori. Appl Environl Microbiol 66: 2269–2273. doi: 10.1128/AEM.66.5.2269-2273.2000
    [35] Cañizares P, Gracia I, Gómez LA, et al. (2004) Thermal degradation of allicin in garlic extracts and its implication on the inhibition of the in-vitro growth of helicobacter pylori. Biotechnol Prog 20: 32–37.
    [36] Gail MH, You WC (2006) A factorial trial including garlic supplements assesses effect in reducing precancerous gastric lesions. J Nutr 136: 813S–815S. doi: 10.1093/jn/136.3.813S
    [37] Ernst E (1999) Is garlic an effective treatment for Helicobacter pylori infection? Arch Intern Med 159: 2484–2485. doi: 10.1001/archinte.159.20.2484
    [38] Aydin A, Ersoz G, Tekesin O, et al. (2000) Garlic oil and Helicobacter pylori infection. Am J Gastroenterol 95: 563–564.
    [39] Prasad K, Laxdal VA, Yu M, et al. (1996) Evaluation of hydroxyl radical-scavenging property of garlic. Mol Cell Biochem 154: 55–63.
    [40] Lai PK, Roy J (2004) Antimicrobial and chemopreventive properties of herbs and spices. Curr Med Chem 11: 1451–1460. doi: 10.2174/0929867043365107
    [41] Bakri IM, Douglas CWI (2005) Inhibitary effect of garlic extract on oral bacteria. Arch Oral Biol 50: 645–650. doi: 10.1016/j.archoralbio.2004.12.002
    [42] Ferary S, Auger J (1996) What is the true odour of cut allium? Complementarity of various hyphenated methods: Gas chromatography-mass spectrometry and high-performance liquid chromatography-mass spectrometry with particle beam and atmospheric pressure ionization interfaces in sulphenic acids rearrangement components discrimination. J Chromatogr 750: 63–74.
    [43] Qiutang L, Inder MV (2002) NF-KB regulation in the immune system. Immunology 2: 725–734.
    [44] Yamaoka Y, Kikuchi S, El–Zimaity HMT, et al. (2002) Importance of helicobacter pylori oipA in clinical presentation, gastric inflammation and mucosal interleukin 8 production. Gastroenterology 123: 414–424. doi: 10.1053/gast.2002.34781
    [45] Crabtree JE (1996) Gastric mucosal inflammatory responses to Helicobacter pylori. Aliment Pharmacol Ther 10 Suppl 1: 29–37.
    [46] Reuter HD, Koch HP, Lawson LD (1996 ) Therapeutic effects and applications of garlic and its preparations. In: Garlic: The Science and Therapeutic Application of Allium Sativum and Related Species. 2 Eds., Baltimore: William & Wilkins,162–172.
    [47] Rhodes MJC (1996) Physiologically-active compounds in plant foods: An overview. Proc Nutr Soc 55: 371–384. doi: 10.1079/PNS19960036
    [48] Correa P (1992) Human gastric carcinogenesis: A multistep and multifactorial process-First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res 52: 6735–6740.
    [49] McNulty CAM, Wilson P, Havinga W, et al. (2008) A pilot study to determine the effectiveness of garlic oil capsules in the treatment of dyspeptic patients with helicobacter pylori.Helicobacter 6: 249–253.
    [50] Chowdhury AK, Ahsan M, Islam SN, et al. (1991) Efficacy of aqueous extract of garlic and allicin in experimental shigellosis in rabbits. J Med Res 93: 33–36.
    [51] You WC, Zhang L, Gail MH, et al. (1998) Helicobacter pylori infection, garlic intake and precancerous lesions in a Chinese population at low risk of gastric cancer. Int J Epidemiol 27: 941–944. doi: 10.1093/ije/27.6.941
    [52] Keiss HP, Dirsch VM, Hartung T (2003) Garlic (Allium sativum L.) modulates cytokine expression in lipopolysaccharide-activated human blood thereby inhibiting NF-kappaB activity.J Nutr 133: 2171–2175.
    [53] Salih BA, Abasiyanik FM (2003) Does regular garlic intake affect the prevalence of Helicobacter pylori in asymptomatic subjects? Saudi Med J 10: 1152.
    [54] Cellini L, Di Campli E, Masulli M, et al. (1996) Inhibition of Helicobacter pylori by garlic extract (Allium sativum). FEMS Immunol Med Microbiol 13: 273–277. doi: 10.1111/j.1574-695X.1996.tb00251.x
    [55] Bozin B, Mimica-Dukic N, Samojlik I, et al. (2008) Phenolics as antioxidants in garlic (Allium Sativum L. Alliacea). Food Chem 111: 925–929. doi: 10.1016/j.foodchem.2008.04.071
    [56] Song K, Milner JA (2001) The influence of heating on the anticancer properties of garlic. J Nutr131: 10545–10575.
    [57] Santos J, Almajano MP, Carbo R (2010) Antimicrobial and antioxidant activity of crude onion (Alliam cepa L.) extracts. Int J food Sci Technol: 403–409.
    [58] Dmotoso Go, Oyewopo AO, Kadir RE, et al. (2010) Effects of aqueous extracts of Allium Sativum (Garlic) on semen Parameters in Wistar rats. Int J urology 7: 35–42.
    [59] Corzo-Martinez M, Corzo N, Villamiel M. (2007) Biological properties of onions and garlic.Trends Food Sci Technol 18: 609–625. doi: 10.1016/j.tifs.2007.07.011
    [60] Jakubowski H (2003) On the health benefits of Allium sp. Nutrition 19: 167–168. doi: 10.1016/S0899-9007(02)00953-X
    [61] Aitken RJ, Clar Kson JS, Fishel S (1989) Generation of reactive oxygen species lipid per oxidation and human sperm function. Biol Reprod 41: 183–197. doi: 10.1095/biolreprod41.1.183
    [62] Chen CS, Chao HT, Pan RL, et al. (1997) Hydroxyl radicalinduesed decline in Motility and increase in lipid per oxidation and DNA modification in human sperm. Biochem Mol Biol Int43: 291–303.
    [63] Kaemmerer H, Mitzkat HJ (1985) Ion-exchange chromatography of amino acids in ejaculates of diabeties. Andrologia 17: 485–487.
    [64] Ali BH (2003) Agents ameliorating or augmenting experimental gentamicin nephrotoxicity: Some recent research. Food Chem Toxicol 41: 1447–1452. doi: 10.1016/S0278-6915(03)00186-8
    [65] Agarwal A, Nallella KP, Allamaneni SS, et al. (2004) Role of antioxidants in treatment of male in fertility: An overview of the literature. Reprod Biomed Online 8: 616–627. doi: 10.1016/S1472-6483(10)61641-0
    [66] Pal R, Vaiphei K, Arbab S, et al. (2006) The effect of garlic on isoniazid and rifam picin-induced hepatic in Jury in rats. World J Gastroenterol 28: 636–639.
    [67] Pdraza-chaverri J, Maldonado PD, Medine-Campos ON, et al. (2000) Garlic ameliorates gentamicin nephrotoxicity: Relation to antioxidant enzymes. Free Radic Biol Med 29: 602–611. doi: 10.1016/S0891-5849(00)00354-3
    [68] SU D, Novoselov SV, Sun QA, et al. (2005) Mammalian selenoprotein thioredoxin-glutathione reductase roles in disulfide bond formation and sperm maturation. J Biol Chem 280: 26491–26498. doi: 10.1074/jbc.M503638200
    [69] Anwar MM, Meki AR (2003) Oxidative stress in streptozotocin-induced diabetic rats, effects of garlic oil and melatonin comp. Biochem physiol 135: 539–547. doi: 10.1016/S1096-4959(03)00139-8
    [70] Chauhan NS, Raoch V, Dixit VK (2008) Effect of curculigo orchioides rhizomes on sexual behavior of made rats. Int J Appl Res Nat Products 1: 26–31.
    [71] Lanzotti V (2006) The analysis of onion and garlic. J Chramatogr A 1112: 3–22. doi: 10.1016/j.chroma.2005.12.016
    [72] Guneli E, Tugyan K, Ozturk H, et al. (2008) Effect of melatonin on testicular damage in streptozotocin-induced diabetes rats. Eur Surg Res 40: 354–360. doi: 10.1159/000118032
    [73] Martiez-Cruz F, Guerrero IM, Osuna C (2002) Melatonin prevents the formation of pyrrolized proteins in human plasma induced by hydrogen peroxide. Neurosci Lett 326: 147–150. doi: 10.1016/S0304-3940(02)00020-4
    [74] Mirfard M, Johari H, Mokhtari M, et al. (2011) The effect of Hydro-Alcoholic garlic extract on testis weight and spermatogenesis in mature male rats under chemotherapy with cyclophosphamide. J Fasa Univ Med Sci 3: 123–130.
    [75] Borek C (2006) Garlic reduces dementia and heartdisease risk. J Nutr 136: 810–812. doi: 10.1093/jn/136.3.810S
    [76] Moriguchi T, Saito H, Nishiyama N (1997) Anti-ageing effect of aged garlic extract in the inbred brain atrophy mouse model. Clin Exp Pharmacol Physiol 24: 235–342. doi: 10.1111/j.1440-1681.1997.tb01813.x
    [77] Ushijima M, Sumioka I, Kakimoto M, et al. (1997) Effect of garlic and garlic preparations on physiological and psychological stress in mice. Phytother Res 11: 226–230. doi: 10.1002/(SICI)1099-1573(199705)11:3<226::AID-PTR85>3.0.CO;2-E
    [78] Chauhan NB, Sandoval J (2007) Amelioration of early cognitive deficits by aged garlic extract in Alzheimer's transgenic mice. Phytother Res 21: 629–640. doi: 10.1002/ptr.2122
    [79] Chauhan NB (2006) Effect of aged garlic extract on APP processing and tau phosphorylation in Alzheimer's transgenic model Tg2576. J Ethn Opharmacol 108: 385–394. doi: 10.1016/j.jep.2006.05.030
    [80] Yao M, Nguyen TV, Pike CJ (2005) Beta-amyloid-induced neuronal apoptosis involves c-Jun N-terminal kinasedependent downregulation of Bclw. J Neurosci 25: 1149–1158. doi: 10.1523/JNEUROSCI.4736-04.2005
    [81] Dhingra D, Kumar V (2008) Evidences for the involvement of monoaminergic and GABAergic systems in antidepressantlike activity of garlic extract in mice. Indian J Pharmacol 40: 175–179. doi: 10.4103/0253-7613.43165
    [82] Diaz MR, Sembrano JM (1985) A comparative study of the efficacy of garlic and eugenol as palliative agents against dental pain of pulpal origin. J Philipp Dent Assoc 35: 3–10.
    [83] Kumar GR, Reddy KP (1999) Reduced nociceptive responses in mice with alloxan induced hyperglycemia after garlic (Allium sativum Linn.) treatment. Indian J Exp Biol 37: 662–666.
    [84] Nagourney RA (1998) Garlic: Medicinal food or nutritious medicine? J Med Food 1: 13–28. doi: 10.1089/jmf.1998.1.13
    [85] Nishiyama N, Moriguchi T, Morihara N, et al. (2001) Ameliorative effect of S-allylcysteine, a major thioallyl constituent in aged garlic extract, on learning deficits in senescenceaccelerated mice. J Nutr 131: 1093–1095. doi: 10.1093/jn/131.3.1093S
    [86] Pérez-Severiano F, Salvatierra-Sánchez R, Rodríguez-Pérez M, et al. (2004) SAllylcysteine prevents amyloid-beta peptide-induced oxidative stress in rat hippocampus and ameliorates learning deficits. Eur J Pharmacol 489: 197–202. doi: 10.1016/j.ejphar.2004.03.001
    [87] Kalantari H, Salehi M (2001) The protective effect of garlic oil on hepatototoxicity induced by acetaminophen in mice and comparison with N-acetylcysteine. Saudi Med J 22: 1080–1084.
    [88] Tirranem LS, Borodina EV, Ushakova SA, et al. (2001) Effect of volatile metabolites of dill, radish and garlic on growth of bacteria. Acta Astronaut 49: 105–108. doi: 10.1016/S0094-5765(01)00006-6
    [89] Senapati SK, Dey S, Dwivedi SK, et al. (2001) Effect of garlic (Allium sativum L.) extract on tissue lead level in rats. J Ethnopharmacol 76: 229–332.
    [90] Kannar D, Wattanapenpaiboon N, Savage GS, et al. (2001) Hypocholestrolemic effect of an enteric-coated garlic supplement. J Am Coll Nut 20: 225–231. doi: 10.1080/07315724.2001.10719036
    [91] McNulty CA, Wilson MP, Havinga W, et al. (2001) A Pilot study to determine the effectiveness of garlic oil Capsules in the treatment of dyspeptic patients with Helicobacter Pylori.Helicobacter 6: 249–253. doi: 10.1046/j.1523-5378.2001.00036.x
    [92] Cicero AF, Derosa G, Gaddi A (2004) What do herbalists suggest to diabetic patients in order to improve glycemic control? Evaluation of scientific evidence and potential risks. Acta Diabetol41: 91–98.
    [93] Josling P (2001) Preventing the common cold with a garlic supplement: Adouble-blind, placebo-comtrolled survey. Adv Ther 18: 189–193. doi: 10.1007/BF02850113
    [94] Williamson EM (2005) Interactions between herbal and conventional medicines. Expert Opin Drag Sas 4: 355–378. doi: 10.1517/14740338.4.2.355
    [95] Warren Grant Magnuson clinical center, National Institutes of Health Drug-Nutrient interaction Task force (2003) Maryland USA, Important information to know when you are taking: Coumadin and vitamin k. Acta Diabetol 41: 91–98.
    [96] IZZO AA, Di-carlo G, Borrelli F, et al. (2005) Cardiovascular pharmacotherapy and herbal medicines: The risk of drug interaction. Int J Cardiol 98: 1–14. doi: 10.1016/j.ijcard.2003.06.039
    [97] Tattelman E (2005) Health effects of Garlic. Am Fam Physician 72: 103–106.
    [98] Jabbari A, Argani H, Ghorbanihaghgo A, et al. (2005) Comparision between swallowing and chewing of garlic on levels of serum lipids, cyclosporine, creatinine and lipid peroxidation in renal tnansplant recipient. Lipids Health Dis: 72–77.
    [99] Hagdon Jane (2005) Garlic and organosulfur compounds. Plant Bioact Res Institute, orem, utah, USA, 1–8.
    [100] Lee Moffitt (2005) Herbal supplements that modulate coagulation in cancer patients. Cancer Control Res Institute 12: 149–157. doi: 10.1177/107327480501200302
    [101] Ramsay NA, Kenny MW, Davies G, et al. (2005) Complimentary and alternative medicine use among patients starting warfarin. Br J Haematol 130: 777–780. doi: 10.1111/j.1365-2141.2005.05689.x
    [102] Blumenthal M, Goldberg A, Brinckman J (2004) Herbal medicine: Expanded commission E Monographs. American Botanical Council. Newton: Integrative medicine Communication, 1029 Chestnut street, 139–148.
    [103] Lawson LD (2004) A review of its medicinal effect and indicated active compounds. In: Lawson, LD., Bauer, R., Eds. Phytomedicines of Europe: Chemistry and Biological Activity. Washington, Dc: American Chemical Society Symposium Series 691, 176–209.
    [104] Fakhar H, Hashemi Tayer A (2012) Effect of the garlic pill in comparison with Plavix on platelet aggregation and bleeding Time. Iran J Ped Hematol Oncol 2: 146–152.
    [105] Al-Qattan KK, Thomson M, Al-Mutawa'a S, et al. (2006) Nitric oxide mediates the blood-pressure lowering effect of garlic in the rat two-kidney, one-clip model of hypertension. J Nutr 136: 774S–776S. doi: 10.1093/jn/136.3.774S
    [106] Sharifi AM, Darabi R, Akbarloo N (2003) Investigation of antihypertensive mechanism of garlic in 2K1C hypertensive rat. J Ethnopharmacol 86: 219–224. doi: 10.1016/S0378-8741(03)00080-1
    [107] Morihara N, Sumioka I, Moriguchi T, et al. (2002) Aged garlic extract enhances production of nitric oxide. Life Sci 71: 509–517. doi: 10.1016/S0024-3205(02)01706-X
    [108] Benavides GA, Squadrito GL, Mills RW, et al. (2007) Hydrogen sulfide mediates the vasoactivity of garlic. Proc Natl Acad Sci USA 104: 17977–17982. doi: 10.1073/pnas.0705710104
    [109] Chuah SC, Moore PK, Zhu YZ (2007) S-allylcysteine mediates cardioprotection in an acute myocardial infarction rat model via a hydrogen sulfide-mediated pathway. Am J Physiol Heart Circ Physiol 293: H2693–H2701. doi: 10.1152/ajpheart.00853.2007
    [110] Shouk R, Abdou A, Shetty K, et al. (2014) Mechanisms underlying the antihypertensive effects of garlic bioactives. Nutr Res 34: 106–115. doi: 10.1016/j.nutres.2013.12.005
    [111] Karin Rie, Peter Fakler (2014) Potential of garlic (Allium sativum) in lowering high blood pressure: Mechanisms of action and clinical relevance. Integr Blood Press Control 7: 71–82.
    [112] Ried K (2014) Effect of garlic on blood pressure, serum cholesterol and immunity: Updated meta-analyses and review. J Nutr 71–82.
  • This article has been cited by:

    1. Fabrizio Schifano, Caroline Zangani, Stefania Chiappini, Amira Guirguis, Stefania Bonaccorso, John M. Corkery, 2020, Chapter 6, 978-3-030-33187-0, 95, 10.1007/978-3-030-33188-7_6
    2. Jan van Amsterdam, Johannes G. Ramaekers, Ton Nabben, Wim van den Brink, Use characteristics and harm potential of ecstasy in The Netherlands, 2021, 28, 0968-7637, 107, 10.1080/09687637.2020.1818692
    3. Ángel Romero-Martínez, Marisol Lila, Luis Moya-Albiol, Long-Term Drug Misuse Increases the Risk of Cognitive Dysfunctions in Intimate Partner Violence Perpetrators: Key Intervention Targets for Reducing Dropout and Reoffending, 2019, 16, 1660-4601, 3792, 10.3390/ijerph16203792
    4. Daniel Roy Sadek Habib, Salvatore Giorgi, Brenda Curtis, Role of the media in promoting the dehumanization of people who use drugs, 2023, 0095-2990, 1, 10.1080/00952990.2023.2180383
    5. Negar Sayrafizadeh, Nicole Ledwos, M. Ishrat Husain, David J. Castle, Aggressive behaviours associated with MDMA and psychedelics: a narrative review, 2024, 0924-2708, 1, 10.1017/neu.2024.3
    6. Pascal Kintz, Nadia Arbouche, Pikachu : la nouvelle drogue du violeur ?, 2025, 23520078, 10.1016/j.toxac.2024.12.004
  • Reader Comments
  • © 2019 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

Metrics

Article views(8999) PDF downloads(2350) Cited by(5)

Article outline

/

DownLoad:  Full-Size Img  PowerPoint
Return
Return

Catalog